PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
PLIANT THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.90−0.00 (-0.13%)
Close on Oct 19, 2026
- Market cap
- $55.65M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
77.7%
48M of 62M shares
Institutional holders
86
9 new, 13 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 4 sales
Net sold $163.62K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kevin Tang | 5,859,044 | 9.60% | 13D (active) | Mar 3, 2025 |
| Daniel Schneeberger | 5,509,724 | 8.90% | 13G (passive) | Jun 30, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 3,947,807 | 6.43% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PLRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 6,141,261 | 9.92% | $7.00M | −1,871 | 0.32% |
| ADAR1 Capital Management, LLC | 5,509,724 | 8.90% | $6.28M | +2,924,598 | 0.29% |
| Vanguard Capital Management LLC | 2,440,351 | 3.94% | $2.78M | +97,250 | 0.00% |
| Acadian Asset Management LLC | 2,416,508 | 3.90% | $2.75K | – | 0.00% |
| Two Sigma Investments, LP | 2,262,832 | 3.65% | $2.58M | +9,694 | 0.00% |
| Citadel Advisors LLC | 2,142,226 | 3.46% | $2.44M | −1,084,373 | 0.00% |
| Renaissance Technologies LLC | 2,049,874 | 3.31% | $2.34M | +197,032 | 0.00% |
| Monaco Asset Management SAM | 1,938,747 | 3.13% | $2.21M | – | 0.18% |
| Lynx1 Capital Management LP | 1,798,070 | 2.90% | $2.05M | New | 0.24% |
| BML Capital Management, LLC | 1,546,137 | 2.50% | $1.76M | – | 1.00% |
| Prosight Management, LP | 1,370,233 | 2.21% | $1.56M | −297,367 | 0.27% |
| Peapod Lane Capital LLC | 1,309,013 | 2.11% | $1.49M | +20,435 | 1.01% |
| Woodline Partners LP | 1,296,534 | 2.09% | $1.48M | −370,296 | 0.00% |
| BlackRock, Inc. | 1,151,214 | 1.86% | $1.31M | +54,784 | 0.00% |
| Ikarian Capital, LLC | 1,000,000 | 1.61% | $1.14M | New | 0.12% |
| Eversept Partners, LP | 891,425 | 1.44% | $1.02M | – | 0.05% |
| Marshall Wace, Llp | 835,124 | 1.35% | $952.04K | −160,849 | 0.00% |
| Redmile Group, LLC | 772,126 | 1.25% | $880.22K | – | 0.06% |
| JPMorgan Chase & Co | 681,647 | 1.10% | $783.89K | −180,176 | 0.00% |
| Jacobs Levy Equity Management, Inc | 643,120 | 1.04% | $733.16K | −75,423 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 86 | 48M | 77.7% | 9 / 17 | 27 / 13 | 7M | 9M |
| Q1 2026 | 91 | 50M | 80.8% | 14 / 26 | 26 / 16 | 11M | 6M |
| Q4 2025 | 98 | 47M | 76.0% | 15 / 30 | 34 / 13 | 10M | 16M |
| Q3 2025 | 99 | 53M | 85.1% | 12 / 22 | 42 / 26 | 15M | 14M |
| Q2 2025 | 114 | 52M | 83.2% | 24 / 30 | 39 / 50 | 9M | 16M |
| Q1 2025 | 140 | 58M | 93.5% | 33 / 41 | 39 / 50 | 26M | 32M |
| Q4 2024 | 160 | 65M | 100.0% | 23 / 55 | 43 / 13 | 7M | 6M |
| Q3 2024 | 151 | 64M | 100.0% | 24 / 58 | 33 / 16 | 11M | 7M |
| Q2 2024 | 144 | 64M | 100.0% | 28 / 50 | 34 / 18 | 5M | 7M |
| Q1 2024 | 135 | 66M | 100.0% | 18 / 47 | 36 / 16 | 5M | 2M |
| Q4 2023 | 134 | 64M | 100.0% | 19 / 54 | 33 / 20 | 9M | 3M |
| Q3 2023 | 136 | 60M | 97.2% | 21 / 52 | 34 / 28 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PLRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,746,470 | 2.82% | $1.99M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 615,799 | 0.99% | $702.01K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 471,330 | 0.76% | $537.32K | 0.54% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 206,605 | 0.33% | $235.53K | 0.02% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 153,162 | 0.25% | $192.98K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 120,873 | 0.20% | $152.30K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 104,278 | 0.17% | $108.45K | 0.00% | Jul 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 96,072 | 0.16% | $109.52K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 94,752 | 0.15% | $119.39K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 82,300 | 0.13% | $93.82K | 0.06% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 79,912 | 0.13% | $100.69K | 0.00% | May 31, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 55,129 | 0.09% | $69.46K | 0.01% | May 31, 2026 |
| NVIT Small Cap Value Fund | 50,300 | 0.08% | $57.34K | 0.03% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 46,193 | 0.07% | $52.66K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 31,889 | 0.05% | $36.35K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bernard Coulie | President and CEO, Director | 914,918 | 1.48% | Apr 17, 2026 |
| Minnie Kuo | Chief Operating Officer | 37,806 | 0.06% | Apr 17, 2026 |
| Lily Cheung | Chief Human Resource Officer | 44,847 | 0.07% | Apr 17, 2026 |
| Keith Lamont Cummings | Chief Financial Officer | 297,214 | 0.48% | Apr 17, 2026 |
| Hans Hull | Chief Business Officer | 265,693 | 0.43% | Jan 27, 2025 |
| Eric Lefebvre | Chief Medical Officer | 240,224 | 0.39% | Jan 27, 2025 |
| Mike Ouimette | General Counsel & Corp. Sec'y | 105,544 | 0.17% | Jan 27, 2025 |
| Robert Iannone | Director | – | – | Jul 13, 2026 |
| Flavia Borellini | Director | – | – | Jul 13, 2026 |
| Steve E. Krognes | Director | – | – | Jun 12, 2026 |
| John T. Curnutte | Director | 29,278 | 0.05% | Jun 12, 2026 |
| Gayle A. Crowell | Director | – | – | Jun 12, 2026 |
| Hoyoung Huh | Director | 239,619 | 0.39% | Jun 12, 2026 |
| Darren S. Cline | Director | – | – | Jun 12, 2026 |
| Thomas A. MCCOURT | Director | – | – | Jun 12, 2026 |
| Katharine Knobil | Director | – | – | Jun 9, 2025 |
| David E. I. Pyott | Director | – | – | Jun 9, 2025 |
| Suzanne Louise Bruhn | Director | 35,081 | 0.06% | Jun 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bernard Coulie President and CEO, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −89,375 | $1.28 | $114.40K | 505,601 |
| Lily Cheung Chief Human Resource Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −7,534 | $1.28 | $9.64K | 44,847 |
| Keith Lamont Cummings Chief Financial Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −24,002 | $1.28 | $30.72K | 297,214 |
| Minnie Kuo Chief Operating Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −6,917 | $1.28 | $8.85K | 37,806 |
| Keith Lamont Cummings Chief Financial Officer | Jan 23, 2025 | Award | +56,650 | – | – | 319,258 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 23, 2025 | Award | +35,000 | – | – | 105,544 |
| Hans Hull Chief Business Officer | Jan 23, 2025 | Award | +40,150 | – | – | 251,708 |
| Bernard Coulie President and CEO, Director | Jan 23, 2025 | Award | +162,500 | – | – | 593,017 |
| Eric Lefebvre Chief Medical Officer | Jan 23, 2025 | Award | +45,650 | – | – | 240,224 |
| Lily Cheung Chief Human Resource Officer | Jan 23, 2025 | Award | +25,875 | – | – | 50,425 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 22, 2025 | Sale(10b5-1 plan) | −10,230 | $10.99 | $112.43K | 70,544 |
| Keith Lamont Cummings Chief Financial Officer | Jan 17, 2025 | Sale(10b5-1 plan) | −20,148 | $11.20 | $225.66K | 262,608 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 17, 2025 | Sale(10b5-1 plan) | −13,270 | $11.20 | $148.62K | 80,774 |
| Lily Cheung Chief Human Resource Officer | Jan 17, 2025 | Sale(10b5-1 plan) | −3,740 | $11.20 | $41.89K | 24,550 |
| Eric Lefebvre Chief Medical Officer | Jan 17, 2025 | Sale(10b5-1 plan) | −18,478 | $11.20 | $206.95K | 194,574 |
| Bernard Coulie President and CEO, Director | Jan 17, 2025 | Sale(10b5-1 plan) | −52,419 | $11.20 | $587.09K | 430,517 |
| Hans Hull Chief Business Officer | Jan 17, 2025 | Sale(10b5-1 plan) | −15,936 | $11.20 | $178.48K | 211,558 |
| Bernard Coulie President and CEO, Director | Jul 10, 2024 | Sale(10b5-1 plan) | −38,710 | $11.56 | $447.49K | 482,936 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 10, 2024 | Sale(10b5-1 plan) | −7,656 | $11.56 | $88.50K | 94,044 |
| Eric Lefebvre Chief Medical Officer | Jul 10, 2024 | Sale(10b5-1 plan) | −12,319 | $11.56 | $142.41K | 213,052 |
| Keith Lamont Cummings Chief Financial Officer | Jul 10, 2024 | Sale(10b5-1 plan) | −10,911 | $11.56 | $126.13K | 282,115 |
| Hans Hull Chief Business Officer | Jul 10, 2024 | Sale(10b5-1 plan) | −9,900 | $11.56 | $114.44K | 227,494 |
| Bernard Coulie President and CEO, Director | Jul 9, 2024 | Award | +75,625 | – | – | 521,646 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 9, 2024 | Award | +14,954 | – | – | 101,700 |
| Eric Lefebvre Chief Medical Officer | Jul 9, 2024 | Award | +24,063 | – | – | 225,371 |
| Keith Lamont Cummings Chief Financial Officer | Jul 9, 2024 | Award | +21,313 | – | – | 293,026 |
| Hans Hull Chief Business Officer | Jul 9, 2024 | Award | +19,337 | – | – | 237,394 |
| Keith Lamont Cummings Chief Financial Officer | May 2, 2024 | Option exercise | +21,000 | $2.08 | $43.68K | 271,713 |
| Eric Lefebvre Chief Medical Officer | Jan 23, 2024 | Award | +42,900 | – | – | 199,820 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 23, 2024 | Award | +31,500 | – | – | 86,746 |
| Hans Hull Chief Business Officer | Jan 23, 2024 | Award | +31,500 | – | – | 216,569 |
| Keith Lamont Cummings Chief Financial Officer | Jan 23, 2024 | Award | +55,250 | – | – | 249,855 |
| Lily Cheung Chief Human Resource Officer | Jan 23, 2024 | Award | +26,000 | – | – | 26,795 |
| Bernard Coulie President and CEO, Director | Jan 23, 2024 | Award | +128,150 | – | – | 444,532 |
| Eric Lefebvre Chief Medical Officer | Jan 17, 2024 | Sale(10b5-1 plan) | −10,295 | $17.23 | $177.38K | 156,920 |
| Bernard Coulie President and CEO, Director | Jan 17, 2024 | Sale(10b5-1 plan) | −25,721 | $17.23 | $443.17K | 316,382 |
| Hans Hull Chief Business Officer | Jan 17, 2024 | Sale(10b5-1 plan) | −9,786 | $17.23 | $168.61K | 185,069 |
| Keith Lamont Cummings Chief Financial Officer | Jan 17, 2024 | Sale(10b5-1 plan) | −9,781 | $17.23 | $168.53K | 194,605 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 17, 2024 | Sale(10b5-1 plan) | −5,197 | $17.23 | $89.54K | 55,246 |
| Hans Hull Chief Business Officer | Aug 4, 2023 | Option exercise | +8,791 | $2.08 | $18.29K | 214,905 |
| Hans Hull Chief Business Officer | Aug 4, 2023 | Sale(10b5-1 plan) | −20,050 | $20.01 | $401.20K | 194,855 |
| Hans Hull Chief Business Officer | Aug 3, 2023 | Sale(10b5-1 plan) | +1,800 | $20.00 | $36.00K | 206,114 |
| Hans Hull Chief Business Officer | Aug 3, 2023 | Sale(10b5-1 plan) | −13,069 | $20.00 | $261.38K | 206,114 |
| Hans Hull Chief Business Officer | Aug 3, 2023 | Option exercise | +1,800 | $2.08 | $3.74K | 207,914 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 20, 2023 | Sale(10b5-1 plan) | −4,755 | $17.55 | $83.45K | 60,443 |
| Hans Hull Chief Business Officer | Jul 17, 2023 | Sale(10b5-1 plan) | −17,937 | $18.01 | $323.05K | 219,183 |
| Eric Lefebvre Chief Medical Officer | Jul 17, 2023 | Sale(10b5-1 plan) | −22,321 | $18.01 | $402.00K | 167,215 |
| Keith Lamont Cummings Chief Financial Officer | Jul 17, 2023 | Sale(10b5-1 plan) | −19,771 | $18.01 | $356.08K | 203,999 |
| Bernard Coulie President and CEO, Director | Jul 17, 2023 | Sale(10b5-1 plan) | −70,150 | $18.01 | $1.26M | 342,103 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 17, 2023 | Sale(10b5-1 plan) | −12,778 | $18.01 | $230.13K | 65,198 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 14, 2023 | Award | +27,187 | – | – | 77,976 |
| Eric Lefebvre Chief Medical Officer | Jul 14, 2023 | Award | +43,750 | – | – | 189,536 |
| Keith Lamont Cummings Chief Financial Officer | Jul 14, 2023 | Award | +38,750 | – | – | 223,770 |
| Hans Hull Chief Business Officer | Jul 14, 2023 | Award | +35,156 | – | – | 237,120 |
| Bernard Coulie President and CEO, Director | Jul 14, 2023 | Award | +137,500 | – | – | 412,253 |
| Keith Lamont Cummings Chief Financial Officer | Jun 13, 2023 | Option exercise | +30,750 | $2.08 | $63.96K | 185,020 |
| Keith Lamont Cummings Chief Financial Officer | Jun 9, 2023 | Option exercise | +5,800 | $2.08 | $12.06K | 154,270 |
| Mike Ouimette General Counsel & Corp. Sec'y | Apr 3, 2023 | Sale(10b5-1 plan) | −200 | $27.46 | $5.49K | 50,789 |
| Mike Ouimette General Counsel & Corp. Sec'y | Apr 3, 2023 | Sale(10b5-1 plan) | −2,677 | $26.74 | $71.58K | 50,989 |
| Eric Lefebvre Chief Medical Officer | Mar 30, 2023 | Sale(10b5-1 plan) | −11,245 | $26.52 | $298.22K | 145,786 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ouimette Michael Officer | Jan 22, 2025 | 10,230 | $113.25K | Jan 22, 2025 | Restricted Stock Units |
| P. Hull Johannes Officer | Aug 3, 2023 | 34,919 | $659.97K | Aug 3, 2023 | Exercise of Stock Options |
| Ouimette Michael Officer | Jul 20, 2023 | 4,755 | $84.73K | Jul 20, 2023 | Performance Stock Units |